Business Medical Dialogues
    • facebook
    • twitter
    Login Register
    • facebook
    • twitter
    Login Register
    • Medical Dialogues
    • Speciality Dialogues
    • Education Dialogues
    • Medical Jobs
    • Medical Matrimony
    • MD Brand Connect
    Business Medical Dialogues
    • News
        • Financial Results
        • Hospitals & Diagnostics
        • IT / Health Venture
        • Implants / Devices
        • Insurance
        • Key Movement
        • Pharmaceuticals
        • Policy
        • Technology
        • pharma-news
    • blog
    LoginRegister
    Business Medical Dialogues
    LoginRegister
    • Home
    • News
      • Financial Results
      • Hospitals & Diagnostics
      • IT / Health Venture
      • Implants / Devices
      • Insurance
      • Key Movement
      • Pharmaceuticals
      • Policy
      • Technology
      • pharma-news
    • blog
    • Home
    • Rivaroxaban

    Tag: Rivaroxaban

    You Searched For "Rivaroxaban"
    Morepen Labs adds blockbuster Rivaroxaban, Vildagliptin, UDCA to API portfolio

    Morepen Labs adds blockbuster Rivaroxaban, Vildagliptin, UDCA to API portfolio

    Farhat Nasim14 Oct 2019 8:06 AM GMT
    While two products Rivaroxaban and Vildagliptin will augment Morepen Lab's presence in the cardiac and diabetic segments respectively, the third produc...
    Bayer Rivaroxaban tablets win CDSCO Committee nod for waiver of local clinical trial; directed to carry Phase IV trial

    Bayer Rivaroxaban tablets win CDSCO Committee nod for waiver of local clinical trial; directed to carry Phase IV trial

    Medical Dialogues Bureau8 Aug 2019 11:58 AM GMT
    New Delhi: The apex drug regulatory body, Central Drugs Standard Control Organisation's (CDSCO) Technical Committee has recommended for grant of...
    Delhi HC allows Natco, Alembic to Export Rivaroxaban of Bayer

    Delhi HC allows Natco, Alembic to Export Rivaroxaban of Bayer

    savita thakur thakur10 March 2017 4:15 AM GMT
    NEW DELHI: In a recent order passed by Delhi High Court, the court has granted the permission to Indian pharmaceuticals companies, Alembic and Natco...

    Popular Stories

    • Email: info@medicaldialogues.in
    • Phone: 011 - 4372 0751

    Website Last Updated On : 27 May 2022 6:45 AM GMT
    Company
    • About Us
    • Contact Us
    • Our Team
    • Reach our Editor
    • Feedback
    • Submit Article
    Ads & Legal
    • Advertise
    • Advertise Policy
    • Terms and Conditions
    • Privacy Policy
    • Editorial Policy
    • Comments Policy
    • Disclamier

    This website is certified by Health On the Net Foundation. Click to verify. This site complies with the HONcode standard for trustworthy health information:
    verify here.

    Search only trustworthy HONcode health websites:

    Medical Dialogues is health news portal designed to update medical and healthcare professionals but does not limit/block other interested parties from accessing our general health content. The health content on Medical Dialogues and its subdomains is created and/or edited by our expert team, that includes doctors, healthcare researchers and scientific writers, who review all medical information to keep them in line with the latest evidence-based medical information and accepted health guidelines by established medical organisations of the world.

    Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement or prescription.Use of this site is subject to our terms of use, privacy policy, advertisement policy. You can check out disclaimers here. © 2020 Minerva Medical Treatment Pvt Ltd

    © 2020 - Medical Dialogues. All Rights Reserved.
    Powered By: Hocalwire
    We use cookies for analytics, advertising and to improve our site. You agree to our use of cookies by continuing to use our site. To know more, see our Cookie Policy and Cookie Settings.Ok
    X
    X